Imaging of Pelvis Has Limited Value in Hepatocellular Cancer

This article originally appeared here.
Share this content:
Imaging of Pelvis Has Limited Value in Hepatocellular Cancer
Imaging of Pelvis Has Limited Value in Hepatocellular Cancer

TUESDAY, June 20, 2017 (HealthDay News) -- For patients with a primary diagnosis of hepatocellular cancer (HCC), imaging of the pelvis rarely provides additional pathologic information, according to a study published online June 14 in the Journal of Gastroenterology and Hepatology.

Janio Szklaruk, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues reviewed medical records for 478 patients with 881 examinations of the abdomen and pelvis who were treated between March 2015 and March 2016. Patients were reviewed for the presence of pathology in the pelvis, which was classified as new or old. Overall, 230 patients underwent magnetic resonance imaging (MRI) of the pelvis and 248 underwent computed tomography (CT).

The researchers found that 80.5 percent of patients had no findings on the CT or MRI of the pelvis, including 81.5 percent of those who had CT and 79.6 percent of those who had MRI. Findings in the pelvis were seen in 93 patients, which were most frequently bone metastases, ascites, implants, and bladder wall thickening (31, 27, seven, and five patients, respectively). The findings were related to metastatic disease in 7.9 percent of patients. A new finding in the pelvis was seen in 5.4 percent of all imaging studies.

"The results suggest that the follow-up evaluation of patients with HCC may not include a pelvis exam," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths